Abiopharma

🔍 Balfe Barry Edward (Director)

Company: ICON PLC (ICLR)

Report Date: 2026-08-07

Detailed Transactions and Holdings:

• Acquired 728 shares of Ordinary Shares (Direct)
  Date: 2026-08-07 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,186.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 304 shares of Ordinary Shares at $163.8 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,882.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 78 shares of Ordinary Shares at $165.14 per share (Direct)
  Date: 2026-08-10 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,804.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 728 shares of Restricted Share Units (Derivative)
  Date: 2026-08-07 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 22,258 shares of Restricted Share Units (Derivative)
  Date: 2026-08-10 | Code: A | equity_swap_involved: 0 | shares_owned_after: 22,258.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Acquired 32,635 shares of Stock Options at $166.05 per share (Derivative)
  Date: 2026-08-10 | Code: A | Expires: 2034-08-10 | equity_swap_involved: 0 | shares_owned_after: 32,635.00 | transaction_form_type: 4 | Footnotes: F5, F6

Footnotes:

• F1: Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting.
• F2: These restricted share units were granted on August 7, 2023 and 728 restricted share units vested on August 7, 2026.
• F3: The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
• F4: These restricted share units were granted on August 10, 2026 and are scheduled to vest in three approximately equal installments on March 8, 2027, March 8, 2028, and March 8, 2029.
• F5: These stock options were granted on August 10, 2026 and are scheduled to vest in four approximately equal installments on March 8, 2027, March 8, 2028, March 8, 2029, and March 8, 2030.
• F6: The stock options expire on the eighth anniversary of the grant date, subject to automatic extension until the 30th trading day following any period during which trading is prohibited under the Issuer's Share Trading Policy or applicable law, but in no event later than the tenth anniversary of the grant date.
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.